"MedicalWebPage"

Want an ad free reading experience?

Download PharmEasy App

Banner Image

Register to Avail the Offer

Send OTP

By continuing, you agree with our Privacy Policy and Terms and Conditions

Success Banner Image
Advertisement
Advertisement

Corbevax And Zycov-D: Everything You Need To Know About These Vaccines

By Nishkak +2 more

Introduction

Covid-19 cases are currently under control, especially after the aggressive vaccination drives. Embracing the new normal, schools have finally reopened, with children thrilled at the idea of meeting their friends, physically sitting in the classrooms and enjoying some time away from home. To protect our kids while letting them enjoy their childhood, the government has approved some vaccines which are already being given to children.  


After initially approving only ZyCov-D, the government of India has approved another vaccine, the Corbevax, to boost the vaccination drive, in addition to Covaxin which was first approved for teens in India. The increasing number of approved vaccines from different manufacturers has led to a rapid immunisation of children against Covid-19. 

Confused about the two new vaccines for children. Read ahead to know everything about ZyCov-D and Corbevax and then make an informed decision. A full course of vaccination for every eligible child is very important so that our lil ones have a strong guard while going to school.

ZyCov-D

The ZyCov-D vaccine is the first vaccine against Covid-19 that has been specifically made and approved for kids. The vaccine is developed by Zydus Cadila, an Ahmedabad based company. The ZyCov-D vaccine has been approved for children over 12 years.

ZyCov-D is a needle-free vaccine, an applicator is used to penetrate the skin and insert the vaccine particle inside the bloodstream. With a 66.66% efficacy rate, the vaccine is based on DNA plasmid technology.

 ZyCoV-D was initially a three-dose vaccine, with each shot being administered four weeks apart but now it has received approval for 2 dose regimen.

As per the press release in April 2022, the vaccine has received approval for children over 12 years. The vaccine will now be administered 28 days apart. 

Corbevax

A 2 two-dose vaccine, the Corbevax has been developed by Hyderabad based Biological E. The vaccine was initially available only for children between 12 to 14, but now it has been approved for children between 5 to 15 years.

Corbevax is a receptor-binding domain vaccine. This simply means that the vaccine inserts a piece of the spike protein of the SARS-CoV-2 virus and uses this to stimulate and prepare the body to fight off any future infection.

Corbevax is administered in a two-dose format, with the second dose due after 28 days.  

Comparison Table

FeaturesZyCoV-DCorbevax
OriginZydus Cadila(Ahmedabad)Dynavax, California; licensed to BioE(Hyderabad)
Nature of the VaccinePlasmid DNA-based vaccineRBD protein subunit vaccine
AdministrationNeedle-free with PharmaJetIntramuscular injection
RegimenAdministered in two doses: day 0 & day 28 (Was initially given in 3 doses)Administered in two doses: day 0 & day 28
Target Demographic after Emergency Use Authorization in India (EUA)Approved for children of age 12 years and aboveApproved for children in the 5-12 years age group.

With more vaccines getting government approvals, selection must be done based on the age, method of administration, availability and the regimen. ZyCov-D is perfect for kids who are scared of needles and Corbevax is administered to kids between 5-12.  

Vaccinate your kids and let them finally be carefree and safeguarded from Covid-19. After all, these vaccines have been proven effective in reducing the probability of serious illness due to Covid-19. Let’s prioritise immunising!

Disclaimer: The information included on this site is for educational purposes only and is not intended to be a substitute for medical treatment by a healthcare professional. Because of unique individual needs, the reader should consult their physician to determine the appropriateness of the information for the reader’s situation.

3
1
Advertisement

You may also like

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments